Since IL-6/STAT3 is also an important mediator of the breast cancer cell-MDSC positive signaling loop [32], targeting key molecules in the IL-6/STAT3 pathways may be a promising therapy for recurrent and drug resistant breast cancers [33]. The gene discussed is IL6; the disease is breast cancer.